Archit Organosys Ltd (ARCHITORG) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Archit Organosys Ltd on NSE and BSE, with an AI summary of each filing.
Announcement of Unaudited Financial result for quarter and half year ended on September 30, 2026.
Financial Result · 04 Nov 2026, 10:08 pm
Archit Organosys Q2 Results: Revenue Surges 94.8% YoY While Net Profit Remains Flat Archit Organosys reported a 94.8% YoY surge in Q2 revenue from operations to ₹63.99 cr compared to ₹32.86 cr in Q2'25, also rising 72.6% QoQ from ₹37.08 cr. However, Q2 net profit stood flat at ₹1.54 cr versus ₹1.54 cr in Q2'25 and ₹1.45 cr in Q1'27, restrained by elevated stock-in-trade purchases. For H1'27, revenue rose 53.0% YoY to ₹101.08 cr, while net profit declined 16.3% YoY to ₹2.99 cr with diluted EPS at ₹1.46. Total borrowings fell sharply to ₹7.21 cr.
Outcome Of Board Meeting
Outcome · 04 Nov 2026, 9:58 pm
Archit Organosys Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh) ■ Revenue: 6,399 (+94.7% YoY | +72.6% QoQ) ■ EBITDA: 316 (+16.7% YoY | -6.4% QoQ) ■ EBITDA Margin (%): 4.9 (-330 bps YoY | -416 bps QoQ) ■ PAT: 154 (+0.3% YoY | +6.7% QoQ) ■ EPS (INR): 0.75 (+0.0% YoY | +5.6% QoQ)
Archit Organosys Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve the unaudited financial result ....
Intimation · 04 Nov 2026, 5:30 am
Archit Organosys Board Meeting Scheduled for Nov'26 to Consider Q2 Results Archit Organosys Limited has scheduled its Board of Directors meeting on 4th Nov'26 to consider and approve the unaudited financial results for the quarter and half-year ended 30th Sep'26. In accordance with SEBI insider trading regulations, the trading window for designated persons, promoters, and directors was closed on 1st Oct'26 and will reopen 48 hours following the public dissemination of the financial results.
Voting result for 33rd Annual General Meeting
Annual General Meeting · 02 Oct 2026, 11:23 pm
Outcome of 33rd Annual general Meeting
Annual General Meeting · 30 Sept 2026, 11:55 pm
Corrigendum to the Annual Report for FY 2025-26
Others (Uncategorized) · 25 Sept 2026, 1:33 am
Corrigendum to the Notice of 33rd Annual General Meeting to be held on 30.09.2026
Annual General Meeting · 25 Sept 2026, 12:38 am
Outcome of the board meeting held on 23.09.2026 for withdrawal of agenda items from notice convening ensuing annual general meeting
Others (Uncategorized) · 24 Sept 2026, 12:18 am
Notice of Annual General Meeting to be held on 30th September, 2026
Annual General Meeting · 08 Sept 2026, 1:21 am
Annual report for F.Y. 2025-26
Others (Uncategorized) · 08 Sept 2026, 1:16 am
Record date for purpose of Final Dividend
Dividend · 04 Sept 2026, 1:56 am
Archit Organosys Sets Record Date for FY26 Final Dividend Archit Organosys Limited (BSE: 524640) set 23rd Sep'26 as the record date to determine shareholder eligibility for its FY26 final dividend. The company's book closure period will run from 24th Sep'26 to 29th Sep'26. This dividend remains subject to shareholder approval at the 33rd Annual General Meeting scheduled for 30th Sep'26. Upon approval, the payout will be executed within 30 days of the AGM to all beneficial owners and physical shareholders registered by the close of business on the record date.
Outcome of Board Meeting for Issue and allotment of Equity Shares on preferential Basis
Others (Uncategorized) · 03 Sept 2026, 11:57 pm
Outcome of Board Meeting for increase in authorised share capital and issue and allotment of Equity Shares through preferential basis
Outcome · 03 Sept 2026, 11:56 pm
Archit Organosys Approves Capital Hike and Share Swap Acquisition of Archit Life Science On 3rd Sep'26, Archit Organosys approved increasing its authorised share capital from Rs 25 crore to Rs 60 crore to facilitate a major acquisition. The board cleared a preferential issue of 3,72,48,344 equity shares via a share swap at Rs 65 per share. This issuance funds the acquisition of a 92.20% stake (1,86,24,172 shares) in Archit Life Science Limited, valuing the target's shares at Rs 130 each. The strategic transaction involves promoter and non-promoter allottees and remains subject to final shareholder and regulatory approvals.
Archit Organosys Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/09/2026 ,inter alia, to consider and approve proposal for issue of securities ....
Intimation · 28 Aug 2026, 1:10 am
Archit Organosys to Consider Fundraising via Equity Issuance Archit Organosys Limited's Board of Directors will meet on 3rd Sep'26 to evaluate a proposal for raising funds. The company is considering issuing equity shares, share warrants, or other equity-based securities through a preferential issue on a private placement basis, or other permissible modes. The final decision is subject to necessary approvals. In connection with this, the trading window for promoters, directors, and senior management has been closed and will reopen 48 hours after the meeting's outcome is publicly disclosed.
Approval of Unaudited Financial Result for the quarter ended 30th June, 2026
Financial Result · 12 Aug 2026, 7:27 pm
Archit Organosys Q1FY27 Results: Profit Declines Amid Higher Expenses Archit Organosys reported a 28.8% YoY decline in net profit to ₹144.70 Lacs for the quarter ended 30th Jun'26, down from ₹203.59 Lacs. Revenue from Operations grew 11.7% YoY to ₹3,708.24 Lacs. However, the profit contraction was driven by a sharp 140% YoY surge in the cost of materials consumed to ₹1,767.88 Lacs. On a QoQ basis, net profit fell by 28.4%. The company's basic EPS for the quarter stood at ₹0.71, compared to ₹0.99 in the prior-year and preceding quarters.
Approval of Unaudited Financial Result for the Quarter ended on 30th June, 2026
Outcome · 12 Aug 2026, 7:15 pm
Archit Organosys Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lacs) ■ Revenue: 3,708 (+11.7% YoY | +1.6% QoQ) ■ EBITDA: 337 (-18.6% YoY | -31.1% QoQ) ■ EBITDA Margin (%): 9.1 (-338 bps YoY | -432 bps QoQ) ■ PAT: 145 (-28.9% YoY | -28.4% QoQ) ■ EPS (INR): 0.71 (-28.3% YoY | -28.3% QoQ)
Archit Organosys Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....
Intimation · 12 Aug 2026, 5:30 am
Archit Organosys Board Meeting Scheduled for Q1 FY27 Results Archit Organosys (BSE: 524640) will hold a Board of Directors meeting on 12 Aug'26 to consider and approve its unaudited financial results for the quarter ending 30 Jun'26. In compliance with SEBI insider trading regulations, the trading window for promoters, directors, and other connected persons has been closed from 01 Jul'26. The window will reopen 48 hours after the financial results are publicly announced. This meeting will provide the first financial update for fiscal year 2026-27.
Approval of financial results for the quarter and financial year ended on March 31, 2026.
Financial Result · 16 May 2026, 7:36 pm
Archit Organosys Limited - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lacs) ■ Revenue: 3650 (-15.5% YoY | -4.9% QoQ) ■ EBITDA: 489 (+10.8% YoY | +4.6% QoQ) ■ EBITDA Margin (%): 13.4 (+318 bps YoY | +122 bps QoQ) ■ PAT: 202 (+0.2% YoY | -16.9% QoQ) ■ EPS (INR): 0.99 (+1.0% YoY | -16.8% QoQ)
The Board approved dividend subject to approval of Shareholders at ensuing AGM.
Dividend · 16 May 2026, 7:14 pm
Archit Organosys Q4FY26 Results and Dividend Recommendation Archit Organosys reported Q4FY26 PAT of ₹202.22 Lacs, down 16.9% QoQ but flat YoY. Revenue from operations was ₹3,649.89 Lacs, down 5.0% QoQ. For the full year FY26, PAT grew 59.0% YoY to ₹803.21 Lacs, while revenue increased 12.2% YoY to ₹14,095.25 Lacs. The Board has recommended a final dividend of ₹1.00 per share (10%) for FY26. The auditor, G.K. Choksi & Co., issued an unmodified opinion on the standalone financial results for the quarter and year ended 31st Mar'26.
Approval of Audited financial results for the quarter and financial year ended on 31st March, 2026.
Outcome · 16 May 2026, 7:11 pm
Archit Organosys Limited - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lacs) ■ Revenue: 3650 (-15.5% YoY | -4.9% QoQ) ■ EBITDA: 489 (+10.8% YoY | +4.6% QoQ) ■ EBITDA Margin (%): 13.4 (+318 bps YoY | +122 bps QoQ) ■ PAT: 202 (+0.2% YoY | -16.9% QoQ) ■ EPS (INR): 0.99 (+1.0% YoY | -16.8% QoQ)
Archit Organosys Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/05/2026 ,inter alia, to consider and approve Update on board meeting
Intimation · 16 May 2026, 5:30 am
Archit Organosys Sets Board Meeting for Q4FY26 Results and Dividend Archit Organosys has scheduled a Board of Directors meeting for 16 May'26 to consider and approve audited financial results for the quarter and year ended 31 Mar'26. The board will also consider recommending a final dividend for FY26, subject to shareholder approval at the subsequent AGM. In compliance with SEBI regulations, the trading window for insiders has been closed since 01 Apr'26 and will reopen 48 hours after the financial results are made public.
Archit Organosys Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/05/2026 ,inter alia, to consider and approve Audited Financial results ....
Intimation · 16 May 2026, 5:30 am
Archit Organosys to Announce Q4'26 & FY26 Results on May 16 Archit Organosys has scheduled a Board of Directors meeting on Sat, 16 May '26 to consider and approve the audited financial results for the quarter and year ended Mar 31, 2026. The trading window for designated persons has been closed since Apr 1, 2026, in compliance with SEBI regulations. The window will reopen 48 hours after the financial results are made public. This meeting is a key event for investors monitoring the company's full-year and final quarter performance.
Reply to Clarification on Price Movement.
Others (Uncategorized) · 25 Apr 2026, 1:34 am
Archit Organosys Clarifies Share Price Movement In a response to the BSE dated 24th Apr'26, Archit Organosys addressed a query regarding significant share price movement. The company stated it has no undisclosed price-sensitive information or impending corporate actions that would influence the stock's performance. Management attributed the recent price and volume behavior purely to market conditions, confirming it is not connected to the movement. The company affirmed its continued compliance with all SEBI disclosure requirements and assured timely intimation of any future material events to the exchange.
The Exchange has sought clarification from Archit Organosys Ltd on April 24, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Others (Uncategorized) · 25 Apr 2026, 12:23 am
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Suchit Amin & PACs
Acquisition/ Disposal of Shares · 20 Mar 2026, 8:46 pm
Archit Organosys: Promoter Suchit Amin Increases Stake via Open Market Purchase Promoter Suchit Kandarp Amin acquired 4,263 equity shares (0.02% of total capital) of Archit Organosys Ltd via an open market purchase on 19th Mar'26. Following the transaction, his total holding increased from 17,76,458 shares (8.66%) to 17,80,721 shares (8.68%). The company's total equity share capital remains unchanged at 2,05,20,723 shares. This disclosure was made under SEBI's SAST Regulations, 2011, for the acquirer and Persons Acting in Concert (PAC).